Menarini Obtains European Commission Approval For The Use Of ELZONRIS (tagraxofusp) In The Treatment Of Plasmacetoid Blast Dendritic Cell Neoplasm (NC

The Menarini Group, a privately-held Italian pharmaceutical and diagnostic company, announced that it has been granted marketing authorization by the European Commission for ELZONRIS (tagraxofusp) as a monotherapy for the first-line treatment of adult patients with plasmacytoid blast dendritic cell neoplasm (NCDPB), an aggressive hematologic malignancy with adverse consequences. The Commission's decision follows the positive opinion issued in November 2020 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in November 2020, and is based on the largest clinical trial prospective study never carried out on patients ELZONRIS has achieved orphan drug designation in Europe and becomes the first treatment approved for patients with NCDPB, the first approved treatment targeting CD123, as well as the first treatment to address these unmet medical needs, in Europe . “For the first time, European patients with NCDPB will have the opportunity to receive treatment tailored to this aggressive disease,” said Elcin Barker Ergun , CEO of the Menarini Group. The approval of ELZONRIS will significantly change the therapeutic approach to the treatment of NCDPB, as it gives clinicians access to targeted therapy to help patients suffering from this terrible disease. We are currently working to make ELZONRIS available to European doctors as quickly as possible, in line with our commitment to provide innovative and effective medicines to people with serious health problems. " ELZONRIS is a targeted therapy on CD123 approved by the Food and Drug Administration (FDA) and marketed in the United States since 2019 by Stemline Therapeutics, now part of the Menarini group of companies. ELZONRIS was approved by the FDA in 2018 in the United States, where it is currently available for the treatment of NCDPB in adults and children two years of age or older.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!